Impact of COVID-19 pandemic on use of rituximab among children with difficult nephrotic syndrome

Pediatr Res. 2022 Jul;92(1):3-5. doi: 10.1038/s41390-021-01744-8. Epub 2021 Sep 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19*
  • Child
  • Humans
  • Immunologic Factors
  • Immunosuppressive Agents
  • Nephrotic Syndrome* / drug therapy
  • Pandemics
  • Recurrence
  • Remission Induction
  • Rituximab / therapeutic use
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Immunosuppressive Agents
  • Rituximab